Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18779961 | PREFUSION-STABILIZED HMPV F PROTEINS | July 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18608668 | ORAL VACCINE VIA DENTAL BACTERIA AND EMITTED PEPTIDES TO PREVENT COVID-19 INFECTION | March 2024 | October 2025 | Allow | 19 | 2 | 1 | Yes | No |
| 18597598 | MATERIALS AND METHODS RELATING TO IMMUNOGENIC EPITOPES FROM HUMAN PAPILLOMAVIRUS | March 2024 | October 2025 | Allow | 19 | 2 | 0 | No | No |
| 18436426 | COMPOSITIONS AND METHODS FOR ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS | February 2024 | December 2024 | Allow | 10 | 1 | 0 | No | No |
| 18412674 | VLP Stabilized Vaccine Compositions | January 2024 | May 2025 | Allow | 16 | 3 | 0 | No | No |
| 18269284 | SOLANESOL VACCINE ADJUVANTS AND METHODS OF PREPARING SAME | January 2024 | November 2024 | Allow | 17 | 1 | 1 | No | No |
| 18483662 | IMMUNOSTIMULATORY METHOD | October 2023 | November 2025 | Allow | 25 | 1 | 1 | No | No |
| 18476921 | MERS-CoV Vaccine | September 2023 | October 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18475950 | Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor | September 2023 | July 2025 | Allow | 22 | 1 | 0 | No | No |
| 18372556 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE MULTI-TARGETED ANTIGENS | September 2023 | January 2025 | Allow | 16 | 1 | 0 | No | No |
| 18461815 | METHOD FOR QUANTIFYING DNA FRAGMENTS IN A SAMPLE BY SIZE | September 2023 | July 2025 | Allow | 23 | 1 | 0 | No | No |
| 18455151 | RECOMBINANT ADENOVIRUSES AND USES THEREOF | August 2023 | January 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18236676 | CANCER IMMUNOTHERAPY USING VIRUS PARTICLES | August 2023 | March 2025 | Allow | 19 | 2 | 1 | Yes | No |
| 18353421 | Vaccines For Recurrent Respiratory Papillomatosis And Methods Of Using The Same | July 2023 | July 2025 | Allow | 24 | 3 | 0 | No | No |
| 18207752 | METHODS AND COMPOSITIONS FOR TREATING CANCERS | June 2023 | May 2025 | Allow | 23 | 3 | 0 | Yes | No |
| 18329696 | NOVEL VACCINES AGAINST HPV AND HPV-RELATED DISEASES | June 2023 | September 2024 | Allow | 16 | 1 | 0 | No | No |
| 18328812 | RECOMBINANT RHABDOVIRUS ENCODING FOR CCL21 | June 2023 | May 2025 | Allow | 24 | 2 | 1 | No | No |
| 18323493 | ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS | May 2023 | September 2024 | Allow | 16 | 1 | 0 | No | No |
| 18199044 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE HUMAN PAPILLOMAVIRUS FORMULATIONS | May 2023 | November 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18319865 | IMMUNE COMPLEX | May 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18318325 | NOVEL VESICULAR STOMATITIS VIRUS AND VIRUS RESCUE SYSTEM | May 2023 | January 2025 | Allow | 20 | 2 | 0 | Yes | No |
| 18317616 | NOVEL ONCOLYTIC VIRUSES FOR SENSITIZING TUMOR CELLS TO KILLING BY NATURAL KILLER CELLS | May 2023 | January 2025 | Allow | 20 | 2 | 0 | No | No |
| 18142697 | VACCINE COMPOSITIONS | May 2023 | October 2025 | Abandon | 29 | 3 | 0 | No | No |
| 18306082 | SEXUALLY TRANSMITTED DISEASE VACCINES | April 2023 | November 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18194864 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS THROUGH STIMULATED INNATE IMMUNITY IN COMBINATION WITH ANTIVIRAL COMPOUNDS | April 2023 | October 2025 | Abandon | 30 | 2 | 0 | No | No |
| 18192352 | RSV F Protein Mutants | March 2023 | March 2025 | Allow | 23 | 2 | 0 | No | No |
| 18021258 | Vaccine Composition for Preventing Tuberculosis Comprising Chorismate Mutase | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18158940 | Compositions and Methods for Promoting Immune Responses to Human Immunodeficiency Virus | January 2023 | August 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18151182 | NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE THEREOF | January 2023 | November 2024 | Allow | 22 | 2 | 0 | No | No |
| 18149922 | CXCR4/CXCR7 Blockade and Treatment of Human Papilloma Virus-Associated Disease | January 2023 | March 2025 | Abandon | 27 | 2 | 1 | No | No |
| 18069159 | HETEROLOGOUS COMBINATION PRIME:BOOST THERAPY AND METHODS OF TREATMENT | December 2022 | November 2024 | Abandon | 23 | 1 | 1 | No | No |
| 18074302 | HEPATITIS B VACCINES AND USES OF THE SAME | December 2022 | October 2024 | Allow | 22 | 2 | 1 | Yes | No |
| 18058619 | Modified Marek's Disease Virus, and Vaccines Made Therefrom | November 2022 | January 2025 | Allow | 26 | 3 | 0 | No | No |
| 18057201 | METHOD FOR SEQUENCING A DIRECT REPEAT | November 2022 | November 2024 | Abandon | 24 | 2 | 0 | No | No |
| 18053283 | SYSTEMS AND METHODS TO IMPROVE VACCINE EFFICACY | November 2022 | October 2025 | Abandon | 35 | 4 | 0 | Yes | No |
| 17997886 | VACCINES AGAINST VIRAL PATHOGENS | November 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17995722 | TARGETED DELIVERY OF AN INHIBITOR OF MIR-21 TO MACROPHAGES FOR THE TREATMENT OF PULMONARY FIBROSIS | October 2022 | January 2026 | Allow | 39 | 1 | 0 | No | No |
| 17822213 | DETECTION OF SARS-COV-2 USING RNA MULTI-ARM JUNCTION LOGIC GATES | August 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17904897 | METHOD FOR DETECTING SINGLE-STRANDED RNA VIRUS | August 2022 | March 2026 | Allow | 43 | 2 | 0 | Yes | No |
| 17794913 | ONCOLYTIC VIRUS COMPOSITIONS INCLUDING IL-15 COMPLEX AND METHODS FOR THE TREATMENT OF CANCER | July 2022 | December 2025 | Allow | 41 | 1 | 0 | No | No |
| 17853783 | HPV VACCINES | June 2022 | November 2025 | Abandon | 41 | 4 | 0 | No | Yes |
| 17835949 | DNA POLYMERASE, APTAMER, WARM-START DNA POLYMERASE AND PREPARATION METHODS AND APPLICATION THEREOF | June 2022 | October 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17835071 | THERAPEUTIC MRNA VACCINE FOR MALIGNANCIES | June 2022 | September 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17781826 | VACCINE CONJUGATES | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17749163 | Lipid-DNA Labeling of Lipid Bilayer Particles for Amplification Quantitation | May 2022 | May 2025 | Allow | 36 | 1 | 0 | No | No |
| 17777589 | HYBRID VIRUS-LIKE PARTICLES AND USE THEREOF AS A THERAPEUTIC HEPATITIS B VACCINE | May 2022 | September 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17775562 | BIOMARKERS FOR NANOPARTICLE COMPOSITIONS | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17726431 | NEUTRALIZING ANTIBODY TESTING AND TREATMENT | April 2022 | July 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17769839 | HLA-RESTRICTED VCX/Y PEPTIDES AND T CELL RECEPTORS AND USE THEREOF | April 2022 | December 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17721134 | IMMUNE CELLS EXPRESSING RECEPTOR SPECIFIC TO CLASS I MHC MOLECULE AND INTERFERING RNA FOR HLA GENE | April 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17766015 | A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA | April 2022 | November 2025 | Allow | 43 | 1 | 1 | No | No |
| 17701270 | BIOMATERIAL-BASED ANTIGEN FREE VACCINE AND THE USE THEREOF | March 2022 | August 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17761064 | MATERIALS AND METHODS FOR DETECTING HUMAN PAPILLOMA VIRUS | March 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17639949 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALS | March 2022 | October 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17682358 | RECOMBINANT VACCINE AGAINST MAREK'S DISEASE AND NEWCASTLE DISEASE | February 2022 | November 2024 | Allow | 33 | 4 | 0 | Yes | No |
| 17670811 | SARS CoV-2 INFECTIVITY DETERMINATION ASSAY | February 2022 | December 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17590353 | ASSAY FOR NEUTRALIZING ANTIBODY TESTING AND TREATMENT | February 2022 | June 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17578312 | VACCINE COMBINATION AND METHOD FOR USING THE SAME | January 2022 | August 2025 | Allow | 43 | 2 | 0 | No | No |
| 17563787 | METHODS FOR TREATING CANCER WITH ACTIVATING ANTIGEN CARRIERS | December 2021 | August 2025 | Abandon | 44 | 4 | 0 | Yes | No |
| 17596847 | An Aptamer for Dengue Virus and Related Methods and Products | December 2021 | August 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17621033 | IMPROVED THERAPEUTIC COMPOSITION COMPRISING HEPATITIS B ANTIGEN HAVING S, PRE-S1 AND PRE-S2 PROTEIN, ALUMINIUM PHOSPHATE AND INTERFERON-ALPHA AND USE THEREOF FOR TREATMENT OF HEPATITIS B | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17300929 | Assay For Neutralizing Antibody Testing And Treatment | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17596547 | Hepatitis B Virus (HBV) Vaccines and Uses Thereof | December 2021 | July 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17596366 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PD-L1 INHIBITORS | December 2021 | June 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17617209 | MEDICINAL COMPOSITION | December 2021 | August 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17614064 | VIRAL VECTOR | November 2021 | February 2025 | Allow | 39 | 1 | 1 | No | No |
| 17529206 | CROSS PRIMER ISOTHERMAL AMPLIFICATION PRIMER SET FOR DETECTING TOBACCO RINGSPOT VIRUS, KIT AND APPLICATION THEREOF | November 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17610592 | COMPOSITIONS AND METHODS FOR TREATING T CELL EXHAUSTION | November 2021 | March 2025 | Allow | 40 | 4 | 1 | Yes | No |
| 17595119 | ATTENUATED IBV WITH EXTENDED CELL CULTURE AND TISSUE TROPISM | November 2021 | May 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17607573 | INTRINSIC SYSTEM FOR VIRAL VECTOR TRANSGENE REGULATION | October 2021 | July 2025 | Allow | 44 | 1 | 1 | No | No |
| 17507496 | Novel Method for Obtaining Efficient Viral Vector-Based Compositions for Vaccination or Gene Therapy | October 2021 | January 2025 | Allow | 39 | 4 | 1 | No | No |
| 17594494 | Methods for Inducing a Safe Immune Response Against Polio Virus | October 2021 | May 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17603789 | PHAGE TEST KIT | October 2021 | May 2025 | Abandon | 43 | 3 | 0 | No | No |
| 17603125 | USE OF PROBES TO DETECT TOXINOGENIC CYANOBACTERIA, DETECTION METHOD AND CORRESPONDING KITS | October 2021 | August 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17602988 | ONCOLYTIC ADENOVIRAL VECTOR EXPRESSING A MEMBER OF THE B7 FAMILY OF COSTIMULATORY LIGANDS AND ADA | October 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17601557 | TREATMENT FOR RESTORING UREAGENESIS IN CARBAMOYL PHOSPHATE SYNTHETASE 1 DEFICIENCY | October 2021 | December 2024 | Allow | 38 | 1 | 0 | No | No |
| 17493647 | FUCOSYLLACTOSE AS BREAST MILK IDENTICAL NON-DIGESTIBLE OLIGOSACCHARIDE WITH NEW FUNCTIONAL BENEFIT | October 2021 | November 2024 | Abandon | 37 | 4 | 0 | No | No |
| 17600588 | HUMAN VACCINE COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | September 2021 | June 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17598659 | AD7-VECTORED VACCINE FOR PREVENTING SARS- COV-2 INFECTION | September 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17598178 | IMMUNOASSAY METHOD AND DETECTION KIT FOR RESPIRATORY TRACT VIRUS | September 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17474240 | Heterologous Prime Boost Vaccine | September 2021 | August 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17438050 | KIT FOR EARLY SCREENING OF LIVER CELL CANCER AND PREPARATION METHOD AND USE THEREOF | September 2021 | April 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17471709 | Method for rescuing influenza virus and composition therefor | September 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17470283 | METHOD FOR DETERMINING IMMUNE COMPETENCE AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | September 2021 | August 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17437266 | CORONAVIRUS VACCINES AND USES THEREOF | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17436183 | HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS | September 2021 | February 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17463618 | SYSTEM AND METHOD FOR DIGITAL REMOTE PRIMARY, SECONDARY, AND TERTIARY COLOR CALIBRATION VIA SMART DEVICE IN ANALYSIS OF MEDICAL TEST RESULTS | September 2021 | May 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17463824 | BIOMARKERS AND USES THEREOF IN THE TREATMENT OF CHRONIC HBV INFECTION | September 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17404105 | GENERATING HPV ANTIGEN-SPECIFIC T CELLS FROM A NAÏVE T CELL POPULATION | August 2021 | July 2025 | Allow | 47 | 2 | 1 | No | No |
| 17424499 | Personalized Immunotherapy for Rejuvenating, Activating and Strengthening Exhausted and Dysfunctional T Cells, Reducing PD-1, and Improving Immune Function | July 2021 | June 2025 | Allow | 47 | 1 | 1 | No | No |
| 17421346 | LIGHT-RESPONSIVE POLYPEPTIDES AND METHODS OF USE THEREOF | July 2021 | December 2024 | Allow | 41 | 2 | 0 | No | No |
| 17361462 | COMBINATION PRODUCT FOR USE IN TUMOR VACCINATION | June 2021 | March 2025 | Abandon | 45 | 0 | 1 | No | No |
| 16759591 | VIRUS-LIKE PARTICLES WHICH CAN BE USED IN THE TREATMENT OF ALLERGIES | June 2021 | June 2025 | Allow | 60 | 1 | 1 | No | No |
| 17311480 | A METHOD FOR PROVIDING A VLP | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17295384 | Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40L | May 2021 | June 2025 | Allow | 49 | 1 | 1 | No | No |
| 17287497 | MUTANT VACCINIA VIRUSES AND USE THEREOF | April 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17309038 | METHODS AND COMPOSITIONS FOR TREATING NEGATIVE-SENSE SINGLE-STRANDED RNA VIRUS | April 2021 | October 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17284087 | PD-L1 PRESENTING PLATELETS REVERSE NEW-ONSET TYPE 1 DIABETES | April 2021 | February 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17221032 | COMPOSITIONS AND METHODS FOR TREATING VULVAR DYSPLASIA | April 2021 | October 2023 | Abandon | 30 | 5 | 1 | No | No |
| 17141885 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | January 2021 | February 2025 | Allow | 49 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ZOU, NIANXIANG.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner ZOU, NIANXIANG works in Art Unit 1671 and has examined 92 patent applications in our dataset. With an allowance rate of 70.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.
Examiner ZOU, NIANXIANG's allowance rate of 70.7% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by ZOU, NIANXIANG receive 2.57 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ZOU, NIANXIANG is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +32.6% benefit to allowance rate for applications examined by ZOU, NIANXIANG. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.2% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 36.4% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 85.7% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 69.2% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.3% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.